Ritonavir-boosted nirmatrelvir: Difference between revisions
(→COVID) |
No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: | ||
*Dosage Forms: | *Dosage Forms: Oral | ||
*Routes of Administration: | *Routes of Administration: | ||
*Common Trade Names: Paxlovid | *Common Trade Names: Paxlovid | ||
| Line 26: | Line 26: | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: | ||
**Renally dosed: if eGFR 30-60, then 150 mg/100 mg dosing | |||
*Pediatric: | *Pediatric: | ||
| Line 35: | Line 36: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
** Many [https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/ drug interactions] | |||
**E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 52: | Line 55: | ||
==Comments== | ==Comments== | ||
*89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population. | *89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population. | ||
==See Also== | ==See Also== | ||
Revision as of 20:26, 18 January 2022
Administration
- Type:
- Dosage Forms: Oral
- Routes of Administration:
- Common Trade Names: Paxlovid
Adult Dosing
COVID
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- Treatment of high risk patients with mild-to-moderate disease
- Initiate within 5 days of symptom onset
Pediatric Dosing
COVID
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- 12 years of age and older weighing at least 40 kilograms
- Treatment of high risk patients with mild-to-moderate disease
- Initiate within 5 days of symptom onset
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Renally dosed: if eGFR 30-60, then 150 mg/100 mg dosing
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Many drug interactions
- E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.